Tissue Regenix Group PLC Notice of results and Investor presentation (9168R)
March 06 2023 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 9168R
Tissue Regenix Group PLC
06 March 2023
Tissue Regenix Group plc
('Tissue Regenix' or the 'Company')
Notice of results and Investor presentation
Tissue Regenix (AIM: TRX), the regenerative medical device
company, will announce its final results for the year ended 31
December 2022 on Tuesday 21 March 2023.
Investor Briefing
Daniel Lee, Chief Executive Officer, and David Cocke, Chief
Financial Officer, will host a live online presentation relating to
the final results via the Investor Meet Company platform at 1.30pm
on Thursday 23 March 2023. The presentation is open to all existing
and potential shareholders.
Investors can sign up to Investor Meet Company for free and
register for the presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
Investors who already follow Tissue Regenix on the Investor Meet
Company platform will be de facto invited.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
finnCap Ltd (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR & IR) Tel: +44(0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field
of regenerative medicine. The Company's patented decellularisation
technology ('dCELL(R)') removes DNA and other cellular material
from animal and human soft tissue, leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or damaged body structures. Current
applications address many critical clinical needs in sports
medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specialises in regenerative
medicine and is dedicated to the development of high quality,
innovative tissue scaffolds, which can enhance healing
opportunities in defects created by trauma and disease.
CellRight(R)'s human tissue products may be used in spine, trauma,
general orthopaedic, dental and ophthalmological surgical
procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFLFITVTIVIIV
(END) Dow Jones Newswires
March 06, 2023 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024